EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-31

Study Completion Date

2021-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients with Advanced EGFRm+ NSCLC

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acquired Resistant Mechanism of the First-generation EGFR TKIs

NCT02804217

Non-small Cell Lung Cancer Aquired Resistance EGFR TKIs

UNKNOWN

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781

Non-Small Cell Lung Cancer

COMPLETED

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164

Non-small Cell Lung Cancer

RECRUITING

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

NCT02098954

Carcinoma, Non-Small Cell Lung EGFR Gene Mutation

RECRUITING PHASE2

A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

NCT01382992

Carcinoma, Non-Small-Cell Lung

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with EGFR mutation and presented secondary resistance to prior first-generation EGFR-TKI should have received biopsy of at least on progressed lesions and are able to provide tissues for pathological examination and NGS testing.All enrolled patients will be followed up to clinical outcome (treatments, tumor response, survival, etc).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonsmall Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of informed consent prior to any study specific procedures.
* Male or female patients aged 18 years and older.
* Histological confirmation of stage IIIB/IV NSCLC.
* Documented EGFR mutation positive .
* WHO Performance Status 0, 1 or 2

Exclusion Criteria

* Any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study.
* Previous (within 6 months) or current treatment with AZD9291.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No